Bill Farley is a seasoned executive with over 25 years of experience in global business development, corporate strategy, and commercialization across the biotechnology and pharmaceutical sectors. In addition to directing NYBAY's activities in Healthcare and Life Sciences, Bill currently serves as Chief Business Officer at Expert Systems, where he leads commercialization efforts for AI and large language model (LLM) platforms supporting drug discovery and development.

​

Previously, Bill served as CEO of ChemDiv, Inc., overseeing a portfolio of 30 assets across 26 companies and managing over $80 million in annual discovery revenues. As VP of Business and Corporate Development at NASDAQ-listed Sorrento Therapeutics, he was instrumental in more than 25 IND submissions, a 505(b)(2) NDA approval and launch, and numerous strategic transactions—some valued at over $3.6 billion—spanning oncology, pain management, and cell therapy.  

 

Earlier in his career, Bill served as Global Vice President at WuXi AppTec, where he generated over $170 million in business across key accounts, and at Hitgen Ltd., where he led global business development and secured multimillion-dollar deals with top-tier pharmaceutical partners.  Bill has held governance and advisory roles at Globestar Therapeutics and Xortx Therapeutics, contributing to strategy, market access, and capital formation.

​

Bill holds a BS in Chemistry from SUNY Oswego and has completed advanced coursework at UC Irvine and Rutgers. A frequent speaker at conferences including BIO and SAPA, Bill is a member of AACR and ASCO, and is a named author on several scientific publications and patents.